Research progress on the clinical application of PCSK9 inhibitors in coronary heart disease

Journal Title: Chinese Journal of Clinical Research - Year 2024, Vol 37, Issue 6

Abstract

Coronary heart disease (CHD) is currently an important cause of mortality among residents in China and worldwide. The incidence of CHD in China is increasing annually. Among the various factors leading to the occurrence of CHD, abnormalities in blood lipids, especially elevated low-density lipoprotein cholesterol(LDL-C), are particularly significant. Epidemiological, genetic, and clinical studies have confirmed its crucial role in the development of CHD. Therefore, effectively controlling LDL-C levels has become paramount in preventing the onset of CHD and reducing mortality rates. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, as novel lipid-lowering medications, effectively lower LDL-C and play a significant role in preventing major adverse cardiovascular events(MACEs). This article provides a review of PCSK9 inhibitors in clinical treatment related to coronary artery atherosclerosis.

Authors and Affiliations

CHEN Renliang, CHEN Fengying

Keywords

Related Articles

Effect progress of complement system in neural repair after spinal cord injury

Spinal cord injury has the characteristics of high mortality and disability rates, and the treatment of spinal cord injury has been a worldwide problem. With the deepening of spinal cord injury research and the advanceme...

Correlation between triglyceride-glucose index and atherosclerosis in type 2 diabetes mellitus

Objective To investigate the the clinical application of triglyceride-glucose (TyG) index and its correlation with atherosclerosis in patients with type 2 diabetes mellitus (T2DM).  Methods From January 2020 to December...

Efficacy and immunological effects of neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer

Objective To investigate the efficacy of neoadjuvant chemotherapy with gemcitabine and cisplatin (GC) in patients with muscle-invasive bladder cancer (MIBC), and its impact on immune function. Methods A retrospective a...

Prognosis of 111 young patients with hypertensive intracerebral hemorrhage: a single center clinical study

<b>Objective</b> To explore the differences in prognosis of young hypertensive intracerebral hemorrhage (HIH) patients with different age, gender, and bleeding sites. <b>Methods</b> A retrospective analysis of 111 young...

Relationship between puerarin and urothelial carcinoembryonic antigen 1 expression in apoptosis and autophagy of esophageal cancer cells

"<b>Objective</b> To explore the molecular mechanism of puerarin on apoptosis and autophagy in esophageal cancer cells. <b>Methods</b> Human esophageal cancer EC109 cells were treated with puerarin at 0, 200, 500, 800...

Download PDF file
  • EP ID EP738304
  • DOI 10.13429/j.cnki.cjcr.2024.06.002
  • Views 36
  • Downloads 0

How To Cite

CHEN Renliang, CHEN Fengying (2024). Research progress on the clinical application of PCSK9 inhibitors in coronary heart disease. Chinese Journal of Clinical Research, 37(6), -. https://europub.co.uk./articles/-A-738304